Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 3.840 +0.070 (+1.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Fate Therapeutics < Previous 1 2 3 4 5 6 7 8 9 Next > Earnings Outlook For Fate Therapeutics February 25, 2022 Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... Via Benzinga 2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch February 08, 2022 Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... Via Benzinga Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? January 14, 2022 One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... Via Benzinga Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today January 05, 2022 Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 December 15, 2021 Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: Via Benzinga 10 Biggest Price Target Changes For Wednesday December 15, 2021 Barclays boosted the price target on Sysco Corporation (NYSE: Via Benzinga The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks December 14, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... Via Benzinga Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma December 14, 2021 Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the... Via Benzinga Hedge Funds Are Selling Vontier Corporation December 11, 2021 Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 December 07, 2021 Upgrades For CarMax Inc (NYSE: Via Benzinga Cathie Wood Likes Fate Therapeutics, Should You? December 01, 2021 The biotech has an interesting pipeline, but it's all early stage products. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 November 09, 2021 Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: Via Benzinga Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript November 05, 2021 FATE earnings call for the period ending October 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial 3 Biotech Stocks to Watch Now October 12, 2021 Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and... Via Benzinga The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO November 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... Via Benzinga Exposures COVID-19 Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain September 14, 2021 Positive news versus poor clinical trial results may determine the future of Fate Therapeutics. Via The Motley Fool Exposures Product Safety The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline October 31, 2021 Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 August 26, 2021 Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: Via Benzinga Benchmarks Pivot Higher Ahead of Volatile Week's End August 20, 2021 The major indexes rebounded from their pre-market slide soon after the open, with help from big-name tech names, though all three are still on track for weekly losses. Via Talk Markets 12 Health Care Stocks Moving In Friday's Intraday Session August 20, 2021 Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 277.... Via Benzinga 58 Biggest Movers From Friday August 23, 2021 Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter... Via Benzinga 38 Stocks Moving In Friday's Mid-Day Session August 20, 2021 Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... Via Benzinga Exposures COVID-19 Why Fate Therapeutics Stock Is Sliding Today August 20, 2021 The positive results the company announced after the bell yesterday didn't meet some lofty expectations. Via The Motley Fool Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations August 20, 2021 Following the market opening Friday, the Dow traded up 0.42% to 35,041.98 while the NASDAQ rose 0.86% to 14,667.29. The S&P also rose, gaining 0.52% to 4,428.90. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Thursday's After-Market Session August 20, 2021 Gainers Geovax Labs (NASDAQ:GOVX) shares... Via Benzinga 11 Health Care Stocks Moving In Friday's Pre-Market Session August 20, 2021 Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 74.65% to $7.51. The market value of their outstanding shares is at $47.5 million. Agile Therapeutics (NASDAQ:AGRX... Via Benzinga The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data August 20, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... Via Benzinga Exposures COVID-19 Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response August 20, 2021 Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021... Via Benzinga Fate Stock Collapses As Investors Question Its Cancer Drug's Durability August 19, 2021 Fate Therapeutics unveiled mixed results for its lymphoma treatment late Thursday, and Fate stock crumbled in after-hours action. Via Investor's Business Daily The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck August 19, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.